Skip to main content
Premium Trial:

Request an Annual Quote

Optivia Inks Drug-Interaction Collaboration with FDA

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Optivia Biotechnology today said that it will collaborate with the US Food and Drug Administration on identifying potentially harmful drug-dietary supplement interactions.

Under the collaboration, seven key drug transporters associated with drug-drug interactions will be examined using Optivia's in vitro transporter technology platform, which uses polarized mammalian cell assays that closely model human biology. The collaboration will assess the ability of certain dietary supplements, such as black cohosh, green tea, ginko biloba, kava, usnic acid,0 and others, to affect various drug transporters.

The goal of the collaboration is to identify potentially harmful drug-dietary supplement interactions, such as the interaction of acetaminophen and other drugs associated with liver toxicity, said Menlo Park, Calif.-based Optivia.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.